Intervention treatment of established neutropenia with human recombinant granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in patients undergoing cancer chemotherapy

Gerhartz, H.; Stern, Angelika C.; Wolf-Hornung, B.; Kazempour, Michael; Schmetzer, Helga; Gugerli, U. S.; Jones, Thomas C.; Wilmanns, W.

doi:10.1016/0145-2126(93)90063-q

Cited by 23 publications

(10 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, if found to be successful, the selective administration of colony-stimulating factors to afebrile patients with neutropenia would limit an expensive therapy to those most likely to benefit. Gerhartz et al 20 attempted to evaluate GM-CSF in afebrile patients. However, not all patients in their study had severe neutropenia, some were already hospitalized, and various types and doses of GM-CSF were used.…”

Section: Discussionmentioning

confidence: 99%

Granulocyte Colony-Stimulating Factor in Severe Chemotherapy-Induced Afebrile Neutropenia

Hartmann¹,

Tschetter²,

Habermann³

et al. 1997

N Engl J Med

183

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Granulocyte Colony-Stimulating Factor in Severe Chemotherapy-Induced Afebrile Neutropenia

Hartmann¹,

Tschetter²,

Habermann³

et al. 1997

N Engl J Med

183

View full text Add to dashboard Cite

show abstract

“…First, a double-blind RCT [52] comparing GM-CSF with placebo in 60 patients; second, a threearm RCT [53] using prophylactic G-CSF in two arms and therapeutic G-CSF in the third arm, in 33 non-small lung cancer patients; and last, a RCT [54] comparing G-CSF with placebo in 138 patients. Overall, these small RCTs showed a decreased duration of neutropenia in the CSF arms, but failed to show other clinical benefi ts.…”

Section: Use Of Csf In Afebrile Neutropeniamentioning

confidence: 99%

Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients

et al. 2009

View full text Add to dashboard Cite

Neutropenia is a common complication of cancer chemotherapy. Colony-stimulating factors (CSF) may be used to avoid neutropenia-associated complications. The Spanish Society of Medical Oncology (SEOM) recently constituted a working group to review the main issues concerning the use of CSF and carried out a consensus process about the use of CSF in cancer patients, held in Madrid on 26 May 2006. The group concluded the following recommendations: prophylactic use of CSF is recommended when a rate of febrile neutropenia (FN) higher than 20% is expected without the use of CSF or when additional risk factors for neutropenia exist; therapeutic use of CSF is recommended in order to treat FN episodes but not to treat afebrile neutropenic episodes. In addition, the use of CSF is considered effective when used to mobilise stem cells before high-dose chemotherapy and when used for chemotherapy schedule optimisation in dose-dense and in dose-intense regimens.

show abstract

Section: Therapeutic Usementioning

confidence: 99%

“…This strategy has been tried for patients either with [54,55] or without [56,57] fever. Although no randomised studies of either G-CSF [56] or GM-CSF [57] have shown benefit for adult patients with neutropenia but no fever, there may be some benefit for certain patients with febrile neutropenia. In a randomised double-blind study, Mitchell et al [54] administered either G-CSF or a placebo to a heterogeneous group of 112 children with a variety of cancers who had been admitted for 186 episodes of febrile neutropenia after intensive chemotherapy.…”

Section: Therapeutic Usementioning

confidence: 99%

Haemopoietic Growth Factors in Paediatric Oncology

Wagner

Furman

2001

Paediatric Drugs

View full text Add to dashboard Cite

Recombinant haemopoietic growth factors (HGFs) are an attractive adjunct to reduce morbidity from chemotherapy regimens and their use has become widespread in paediatric oncology. Although patients receiving HGFs often have faster haematological recovery after intensive chemotherapy, this does not always translate into meaningful clinical benefits. This article reviews the clinical effectiveness of HGFs in a variety of different contexts. Most published studies have used granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) as prophylaxis to ameliorate the subsequent neutropenia following intensive chemotherapy. These 2 agents have also been used to mobilise peripheral blood stem cells for autologous transplantation. HGFs specific for anaemia and thrombocytopenia are currently in paediatric clinical trials and it is hoped that the proper context and administration strategy can be found to make their use clinically effective. This article also reviews data on toxicity, specifically focusing on differences between various formulations of growth factors. HGFs are expensive, and cost-benefit analyses reviewed in this article give an important perspective on the financial aspects of paediatric cancer care. Because HGFs do not benefit every child receiving chemotherapy and overuse increases costs and may result in unnecessary adverse effects, evidence-based guidelines for their rational use in paediatric oncology are proposed.

show abstract

Intervention treatment of established neutropenia with human recombinant granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in patients undergoing cancer chemotherapy

Cited by 23 publications

References 28 publications

Granulocyte Colony-Stimulating Factor in Severe Chemotherapy-Induced Afebrile Neutropenia

Granulocyte Colony-Stimulating Factor in Severe Chemotherapy-Induced Afebrile Neutropenia

Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients

Haemopoietic Growth Factors in Paediatric Oncology

Contact Info

Product

Resources

About